Equity Analysis /
United States of America

US : Allogene Therapeutics, Inc. - ALLO | Upgrading to Outperform With $36 Price Target

    Dane Leone
    Bowen Wu
    Bowen Wu

    Res. Assoc.

    CGS-CIMB
    23 September 2021
    Published by